Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
VLA1701 · 1 trial · 2 indications
within 120 hours of challenge with ETEC strain LSN03-016011/A.
| Arm | Type | Description |
|---|---|---|
| VLA1701 | ACTIVE_COMPARATOR | VLA1701 is an investigational oral vaccine against LT-ETEC (Labile Toxin-Enterotoxigenic E coli) The vaccine is administered orally in 2 doses about 1 week apart. |
| Placebo | PLACEBO_COMPARATOR | The buffer component of VLA1701 will be used as Placebo. The vaccine is administered orally in 2 doses about 1 week apart. |
| Name | Type | Description |
|---|---|---|
| VLA1701 | BIOLOGICAL | VLA1701 is an investigational oral vaccine against LT-ETEC (Labile Toxin-Enterotoxigenic E coli) |
| Placebo | BIOLOGICAL | buffer component of VLA1701 |
| Challenge Strain | OTHER | LSN03-016011/A |
Inclusion Criteria: 1. Healthy male and non-pregnant female subjects aged 18 to \<50 years; 2. BMI of 19.0 to 35.0 kg/m2 3. Willingness to participate after informed consent has been obtained from the subject prior to any study related procedures. 4. Completion of a training session and demonstrati...
VLA1701 is an investigational monoclonal antibody being developed for the prevention or treatment of enterotoxigenic Escherichia coli (ETEC) infection, a cause of diarrhea. It is currently in Phase 2 clinical development and is not yet approved by regulatory authorities.
VLA1701 is a monoclonal antibody, but its specific molecular target has not been disclosed in available information. It is being studied for its ability to address enterotoxigenic Escherichia coli infection, which causes diarrhea.
VLA1701 is being developed by Valneva SE, a biopharmaceutical company. Valneva's stock is traded under the ticker symbol VALN.
VLA1701 is in Phase 2 clinical development. It has completed one Phase 2 trial and is not yet approved by the FDA or other regulatory agencies, meaning it remains an investigational drug.
VLA1701 has been studied in one completed Phase 2 clinical trial, identified as NCT03576183. This trial, titled 'Study Confirming A Human Challenge Model and Investigating The Safety Of VLA1701,' enrolled 34 healthy volunteers in the United States and evaluated the drug's safety in the context of an ETEC challenge model.
No alternative names for VLA1701 have been disclosed in available information. It is identified solely by its development code, VLA1701, and is not known to be marketed under any other name.